

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (JK-80) SOTROVIMAB

PRONUNCIATION soe troe' vi mab

THERAPEUTIC CLAIM Treatment of SARS-CoV-2 infection

CHEMICAL NAMES

1. Immunoglobulin G1 [438-leucine,444-serine], anti-(severe acute respiratory syndrome coronavirus 2 spike glycoprotein receptor-binding domain) (human monoclonal VIR-7831 γ 1-chain), disulfide with human monoclonal VIR-7831 κ -chain, dimer (Source: CAS)
2. Immunoglobulin G1-kappa, anti-[Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) Spike glycoprotein (Peplomer protein, E2)],human monoclonal antibody; γ 1 heavy chain (1-457) [*Homo sapiens* VH (IGHV1-18*01 (93%) –(IGHD)-JH4*02 (93%)) [8.8.20] (1-127) -*Homo sapiens* IGHG1*01 {CH3[M⁸⁸>L(438), N⁹⁴>S(444)} (128-457)] (230-214')-disulfide with κ light chain (1'-214') [*Homo sapiens* V-KAPPA (IGKV3-20*01 (94%) – IGKJ4*01)[7.3.8] (1'-107') -*Homo sapiens* IGKC*01 (108'-214')], dimer (236-236":239-239")-bisdisulfide. Post-translational modifications: K (457) and K (457") deleted, N (307) and N (307") glycosylated (Source: USAN Program chemical consultant)

STRUCTURAL FORMULA

Heavy chain X & X''

QVQLVQSGAE	VKKPGASVKV	SCKASGYPFT	SYGISWVRQA	PGQGLEWMGW	50
ISTYQGNTRY	AQKFGQGRVTM	TTDTSTTTGY	MELRRLRSDD	TAVYYCARDY	100
TRGAWFGESL	IGGFDNWGQG	TLVTVSSAST	KGPSVFPLAP	SSKSTSGGTA	150
ALGCLVKDYF	PEPVTVSWNS	GALTSGVHTF	PAVLQSSGLY	SLSSVVTVPS	200
SSLGTQTYIC	NVNHKPSNTK	VDKKEPKSC	DKTHTCPPCP	APELLGGPSV	250
FLFPPKPKDT	LMISRTPEVT	CVVVDVSHED	PEVKFNWYVD	GVEVHNAKTK	300
PREEQYNSTY	RVVSVLTVLH	QDWLNGKEYK	CKVSNKALPA	PIEKTIISKAK	350
GQPREPQVYT	LPPSRDELTK	NQVSLTCLVK	GFYPSDIAVE	WESNGQPENN	400
YKTTTPVLDS	DGSFFFLYSKL	TVDKSRWQQG	NVFSCSVLHE	ALHSHYTQKS	450
LSLSPGK					457

Light chain X' & X'''

EIVLTQSPGT	LSLSPGERAT	LSCRASQTVS	STSLAWYQQK	PGQAPRLLIY	50'
GASSRATGIP	DRFSGSGSGT	DFTLTISRLE	PEDFAVYCYC	QHDTSLTFGG	100'
GTKVEIKRTV	AAPSVFIFPP	SDEQLKSGTA	SVVCLLNNFY	PREAKVQWKV	150'
DNALQSGNSQ	ESVTEQDSKD	STYLSSTLT	LSKADYEKHK	VYACEVTHQG	200'
LSSPVTKSFN	RGEC				214'

Disulfide bridges location

22-96	22"-96"	23'-89'	23'''-89'''	134'-194'	134'''-194'''	154-210	154"-210"
214'-230	214'''-230'''	236-236"	239-239"	271-331	271'''-331'''	377-435	377"-435"

Glycosylation sites (N)

Asn-307 Asn-307"

MOLECULAR FORMULA

C₆₄₉₂H₁₀₀₆₀N₁₇₄₄O₂₀₃₈S₄₀ . (before post-translational modifications)

MOLECULAR WEIGHT	146.43 kDa (before post-translational modifications)
TRADEMARK	None as yet
SPONSOR	GlaxoSmithKline
CODE DESIGNATIONS	VIR-7831, GSK4182136
<u>CAS</u> REGISTRY NUMBER	2423014-07-5
UNII	1MTK0BPN8V
WHO NUMBER	11766

gbk